ClinicalTrials.gg
CompletedNCT03179345Updated Jun 1, 2020Results posted

Simulated Driving Performance, Daytime Sedation and Cognition in Healthy Volunteers Taking Gralise, Neurontin or Lyrica

A Phase 4 interventional study of Gabapentin and Pregabalin in Healthy, sponsored by Depomed. Completed. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-01.

Sponsored by Depomed · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Sep 2015, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

Phase 4, double-blind, placebo-controlled, four treatment, four sequence crossover study comparing simulated driving performance, daytime sedation and cognition in healthy volunteers administered therapeutic doses of Gralise® (Treatment A), Neurontin® (Treatment B), Lyrica® (Treatment C) and placebo (Treatment D). All doses were administered under fed conditions.

02

Conditions studied

  • Healthy

Keywords

  • Volunteer
  • Pharmacodynamics
  • Pharmacokinetics
03

In context

Lead sponsor

Depomed is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 40 and 80 years of age, inclusive.
  • Body weight > 50 kg and between 18 and 32 kg/m2, inclusive.
  • Able to give .
  • Licensed, experienced driver who had driven at least 3 times a week for the past 3 years and had visual acuity adequate for driving, as assessed by the investigator or designee.
  • Able to complete a 1 hour simulated driving test and demonstrate satisfactory driving skills, as determined by the investigator or designee.
  • Karolinska Sleep Scale (KSS) score of \<=5.
  • Other criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Known history of allergic reaction, or intolerance to gabapentin, pregabalin or any pharmaceutical materials, or any of the ingredients in the protocol-specified meals.
  • Pregnant or lactating or considered at risk of pregnancy.
  • Any medical condition or any laboratory abnormality or abnormality that would, in the opinion of the investigator, contraindicate study participation.
  • Impaired liver function (e.g., [ALT] ≥2 times the [ULN] or ≥2 times ULN), known active hepatic disease (e.g., hepatitis), or evidence of clinically significant liver disease or other condition affecting the liver that may suggest the potential for an increased susceptibility to hepatic toxicity with oral gabapentin or pregabalin exposure.
  • Any history of renal disease that, in the opinion of the investigator, would contraindicate study participation; or subject had significantly impaired renal function as evidenced by an estimated of ≤ 80 ml/min/1.73m2.
  • History or evidence of a sleep disorder, including sleep apnea (obstructive, central or mixed), narcolepsy or primary insomnia.
  • Other criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Gralise® (gabapentin)

    Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.

    Drug: Gabapentin

  • Active comparator
    Neurontin® (gabapentin)

    Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.

    Drug: Gabapentin

  • Active comparator
    Lyrica® (pregabalin)

    Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.

    Drug: Pregabalin

  • Placebo comparator
    Placebo (sugar pill)

    Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.

    Other: Placebo

Interventions

  • Also known as: Gralise®, Neurontin®

  • Also known as: Lyrica®

  • OtherPlacebo

    Also known as: Sugar Pill

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®

    SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.

    Time frame: Baseline and Hour 3 on Day 3

Secondary outcomes

  1. Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®

    SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.

    Time frame: Baseline and Hour 3 on Day 3

  2. Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)

    Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance.

    Time frame: Baseline and Hour 3 on Day 3

  3. Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).

    Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance.

    Time frame: Baseline and Hour 3 on Day 3

  4. Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).

    Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance.

    Time frame: Baseline and Hour 3 on Day 3

  5. Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)

    Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance.

    Time frame: Baseline and Hour 3 on Day 3

  6. Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).

    Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance.

    Time frame: Baseline and Hour 3 on Day 3

  7. Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).

    Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep

    Time frame: Baseline and Hour 3 on Day 3

  8. Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).

    Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. \[1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem\] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints.

    Time frame: Baseline and Hour 3 on Day 3

  9. Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).

    Miles per Hour (mph)

    Time frame: Baseline and Hour 3 on Day 3

  10. Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).

    Miles per Hour (mph)

    Time frame: Baseline and Hour 3 on Day 3

  11. To Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.

    * Number of subjects with Treatment-Emergent Adverse Events (TEAE) * Number of subjects with Serious Adverse Event (SAE) * Number of subjects discontinued due to Adverse Event (AE)

    Time frame: Screening to 1 week after Period 4 discharge

07

Results

Posted May 13, 2020

Participant flow

Participant flow — Overall Study
MilestoneGral First, Then Neur, Lyr, and PlboNeur First, Then Plbo, Gral, and LyrLyr First, Then Gral, Plbo, and NeurPlbo First, Then Lyr, Neur, and Gral
Started8888
Received gralise®8776
Received neurontin®8878
Received lyrica®8788
Received placebo8778
Completed8776
Not completed0112

Outcome measures

PrimaryChange From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®

SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · feet
Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®
feetGralise® (Gabapentin)Neurontin® (Gabapentin)Placebo
Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®0.255 ± 0.07810.395 ± 0.07630.135 ± 0.0770
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.0275 · Mean difference (net): -0.141 · 95% CI -0.266 to -0.016SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo · ANOVA · p = 0.0611 · Mean difference (net): 0.120 · 95% CI -0.006 to 0.245SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®

SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · feet
Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®
feetGralise® (Gabapentin)Lyrica® (Pregabalin)Placebo
Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®0.255 ± 0.07810.356 ± 0.07700.135 ± 0.0770
Statistical analysis
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.1103 · Mean difference (net): -0.102 · 95% CI -0.227 to 0.024SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo · ANOVA · p = 0.0611 · Mean difference (net): 0.120 · 95% CI -0.006 to 0.245SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)

Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · msec
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)
msecGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)0.00 ± 0.0130.00 ± 0.012-0.01 ± 0.012-0.00 ± 0.012
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.9946 · Mean difference (net): -0.00 · 95% CI -0.02 to 0.02SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANCOVA · p = 0.1673 · Mean difference (net): 0.02 · 95% CI -0.01 to 0.04SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.6208 · Mean difference (net): 0.01 · 95% CI -0.02 to 0.03SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).

Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · Number of errors on test
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).
Number of errors on testGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).-0.40 ± 2.484-0.01 ± 2.385-0.64 ± 2.4193.32 ± 2.420
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.8799 · Mean difference (net): -0.40 · 95% CI -5.59 to 4.80SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.9277 · Mean difference (net): 0.24 · 95% CI -4.97 to 5.45SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.1587 · Mean difference (net): -3.73 · 95% CI -8.94 to 1.49SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).

Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · Score on Scale
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).
Score on ScaleGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).-0.00 ± 0.0000.00 ± 0.000-0.00 ± 0.0000.01 ± 0.000
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.7111 · Mean difference (net): -0.00 · 95% CI -0.03 to 0.02SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.9048 · Mean difference (net): -0.00 · 95% CI -0.02 to 0.02SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.3262 · Mean difference (net): -0.01 · 95% CI -0.03 to 0.01SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)

Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · Score on Scale
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)
Score on ScaleGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)0.36 ± 0.6840.82 ± 0.6480.03 ± 0.660-0.01 ± 0.660
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.5950 · Mean difference (net): -0.46 · 95% CI -2.18 to 1.26SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.7057 · Mean difference (net): 0.33 · 95% CI -1.40 to 2.06SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.6741 · Mean difference (net): 0.37 · 95% CI -1.36 to 2.10SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).

Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · Score on Scale
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).
Score on ScaleGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).0.02 ± 0.0210.06 ± 0.0200.00 ± 0.0200.03 ± 0.020
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.0070 · Mean difference (net): -0.05 · 95% CI -0.08 to -0.01SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.5183 · Mean difference (net): 0.01 · 95% CI -0.02 to 0.05SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.5084 · Mean difference (net): -0.01 · 95% CI -0.05 to 0.02SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).

Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · units on a scale
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).
units on a scaleGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS)..774 ± .2985.264 ± .2876.868 ± .2913.264 ± .2914
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.1026 · Mean difference (net): 0.510 · 95% CI -0.104 to 1.124SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.7634 · Mean difference (net): -0.094 · 95% CI -0.711 to 0.523SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.1041 · Mean difference (net): 0.510 · 95% CI -0.107 to 1.127SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).

Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. \[1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem\] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints.

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · scores on a scale
Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).
scores on a scaleGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Vision (blurring, double vision)0.036 ± 0.12740.322 ± 0.12350.249 ± 0.12490.115 ± 0.1249
Energy Level (get up and go)0.099 ± 0.18110.256 ± 0.17430.315 ± 0.17660.331 ± 0.1766
Memory (ability to remember people, places, or thi0.077 ± 0.14980.123 ± 0.14410.125 ± 0.1460-0.041 ± 0.1460
Walking (balance)0.206 ± 0.12450.327 ± 0.11870.405 ± 0.12060.107 ± 0.1206
Interest (in activities)0.046 ± 0.11740.030 ± 0.11300.096 ± 0.11450.070 ± 0.1145
Coordination0.180 ± 0.13380.392 ± 0.12890.350 ± 0.13060.218 ± 0.1306
Tremor (shakiness)-0.103 ± 0.05710.037 ± 0.0555-0.031 ± 0.05560.068 ± 0.0556
Concentration (ability to concentrate on a task)0.080 ± 0.12050.164 ± 0.11480.137 ± 0.11660.182 ± 0.1166
Speech (slurring words)0.035 ± 0.05160.133 ± 0.04930.065 ± 0.05010.103 ± 0.0501
Forgetfulness0.118 ± 0.11280.227 ± 0.10830.175 ± 0.10980.079 ± 0.1099
Sleepiness (fatigue, sedation, tiredness)0.693 ± 0.29280.635 ± 0.28021.176 ± 0.28430.541 ± 0.2844
Moodiness0.181 ± 0.11740.163 ± 0.11440.098 ± 0.11550.100 ± 0.1155
Alertness0.297 ± 0.18540.451 ± 0.17860.607 ± 0.18090.353 ± 0.1809
Attention Span0.020 ± 0.11150.133 ± 0.10700.146 ± 0.10850.015 ± 0.1085
Motivation0.185 ± 0.13380.232 ± 0.12940.368 ± 0.13090.271 ± 0.1309
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.0177 · Mean difference (net): -0.286 · 95% CI -0.521 to -0.051SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.4120 · Mean difference (net): -0.157 · 95% CI -0.536 to 0.222SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.7724 · Mean difference (net): -0.046 · 95% CI -0.362 to 0.270SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.4255 · Mean difference (net): -0.121 · 95% CI -0.423 to 0.180SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.8925 · Mean difference (net): 0.017 · 95% CI -0.229 to 0.262SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.1293 · Mean difference (net): -0.212 · 95% CI -0.487 to 0.063SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.0304 · Mean difference (net): -0.140 · 95% CI -0.266 to -0.014SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.5811 · Mean difference (net): -0.084 · 95% CI -0.384 to 0.217SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.1144 · Mean difference (net): -0.098 · 95% CI -0.220 to 0.024SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.3774 · Mean difference (net): -0.109 · 95% CI -0.352 to 0.135SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.8658 · Mean difference (net): 0.057 · 95% CI -0.613 to 0.727SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.8543 · Mean difference (net): 0.018 · 95% CI -0.179 to 0.216SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.4294 · Mean difference (net): -0.153 · 95% CI -0.537 to 0.231SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.3613 · Mean difference (net): -0.113 · 95% CI -0.357 to 0.132SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.7201 · Mean difference (net): -0.047 · 95% CI -0.305 to 0.212SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.0767 · Mean difference (net): -0.213 · 95% CI -0.448 to 0.023SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.2618 · Mean difference (net): -0.216 · 95% CI -0.597 to 0.165SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.7633 · Mean difference (net): -0.048 · 95% CI -0.366 to 0.269SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.1968 · Mean difference (net): -0.198 · 95% CI -0.502 to 0.105SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.6891 · Mean difference (net): -0.050 · 95% CI -0.296 to 0.197SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.2229 · Mean difference (net): -0.171 · 95% CI -0.447 to 0.106SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.2591 · Mean difference (net): -0.072 · 95% CI -0.197 to 0.054SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.7099 · Mean difference (net): -0.057 · 95% CI -0.359 to 0.246SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.6215 · Mean difference (net): -0.031 · 95% CI -0.154 to 0.092SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.6422 · Mean difference (net): -0.057 · 95% CI -0.302 to 0.187SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.1574 · Mean difference (net): -0.483 · 95% CI -1.157 to 0.190SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.4039 · Mean difference (net): 0.084 · 95% CI -0.115 to 0.282SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.1145 · Mean difference (net): -0.309 · 95% CI -0.695 to 0.076SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.3083 · Mean difference (net): -0.127 · 95% CI -0.372 to 0.119SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.1638 · Mean difference (net): -0.183 · 95% CI -0.443 to 0.0776SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.5101 · Mean difference (net): -0.078 · 95% CI -0.314 to 0.157SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.2285 · Mean difference (net): -0.233 · 95% CI -0.614 to 0.149SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.4612 · Mean difference (net): 0.118 · 95% CI -0.200 to 0.436SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.5190 · Mean difference (net): 0.099 · 95% CI -0.205 to 0.402SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.8479 · Mean difference (net): -0.024 · 95% CI -0.271 to 0.223SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.7808 · Mean difference (net): -0.039 · 95% CI -0.316 to 0.238SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.0083 · Mean difference (net): -0.171 · 95% CI -0.296 to -0.045SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.5068 · Mean difference (net): -0.101 · 95% CI -0.404 to 0.201SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.2725 · Mean difference (net): -0.068 · 95% CI -0.191 to 0.055SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.7498 · Mean difference (net): 0.039 · 95% CI -0.206 to 0.284SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.6554 · Mean difference (net): 0.152 · 95% CI -0.522 to 0.826SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.4143 · Mean difference (net): 0.082 · 95% CI -0.116 to 0.280SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.7761 · Mean difference (net): -0.055 · 95% CI -0.441 to 0.330SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.9697 · Mean difference (net): 0.005 · 95% CI -0.241 to 0.251SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo (Sugar Pill) · ANOVA · p = 0.5118 · Mean difference (net): -0.086 · 95% CI -0.346 to 0.174Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.
SecondaryChange From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).

Miles per Hour (mph)

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · mph
Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).
mphGralise® (Gabapentin)Neurontin® (Gabapentin)Placebo
Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).0.831 ± 0.48440.947 ± 0.46480.851 ± 0.4715
Statistical analysis
  • Gralise® (Gabapentin) vs Neurontin® (Gabapentin) · ANOVA · p = 0.8293 · Mean difference (net): -0.116 · 95% CI -1.178 to 0.947SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo · ANOVA · p = 0.9705 · Mean difference (net): -0.020 · 95% CI -1.089 to 1.049SE of difference estimated by dividing width of 95% CI by 4.
SecondaryChange From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).

Miles per Hour (mph)

Time frame:
Baseline and Hour 3 on Day 3
Reported as:
Least squares mean · mph
Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).
mphGralise® (Gabapentin)Lyrica® (Pregabalin)Placebo
Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).0.831 ± 0.48441.319 ± 0.47130.851 ± 0.4715
Statistical analysis
  • Gralise® (Gabapentin) vs Lyrica® (Pregabalin) · ANOVA · p = 0.3666 · Mean difference (net): -0.488 · 95% CI -1.556 to 0.581SE of difference estimated by dividing width of 95% CI by 4.
  • Gralise® (Gabapentin) vs Placebo · ANOVA · p = 0.9705 · Mean difference (net): -0.020 · 95% CI -1.089 to 1.049SE of difference estimated by dividing width of 95% CI by 4.
SecondaryTo Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.

* Number of subjects with Treatment-Emergent Adverse Events (TEAE) * Number of subjects with Serious Adverse Event (SAE) * Number of subjects discontinued due to Adverse Event (AE)

Time frame:
Screening to 1 week after Period 4 discharge
Reported as:
Number · participants
To Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.
participantsGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
Subjects with TEAE613165
Subjects with SAE0000
Subjects Discontinued due to AE0110

Adverse events

Collected over 7 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gralise® (Gabapentin)—0/28 (0%)6/28 (21.4%)
Neurontin® (Gabapentin)—0/31 (0%)11/31 (35.5%)
Lyrica® (Pregabalin)—0/31 (0%)14/31 (45.2%)
Placebo (Sugar Pill)—0/30 (0%)2/30 (6.7%)
Most frequent other events
Most frequent other events
EventGralise® (Gabapentin)Neurontin® (Gabapentin)Lyrica® (Pregabalin)Placebo (Sugar Pill)
SomnolenceNervous system disorders3/287/314/311/30
DizzinessNervous system disorders3/284/316/310/30
HeadacheNervous system disorders1/280/315/311/30
Euphoric moodPsychiatric disorders1/282/313/310/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Gral First, Then Neur, Lyr, and PlboNeur First, Then Plbo, Gral, and LyrLyr First, Then Gral, Plbo, and NeurPlbo First, Then Lyr, Neur, and GralTotal
Mean49.0 ± 5.3247.6 ± 5.2951.0 ± 9.3546.8 ± 4.0648.6 ± 6.23
Sex: Female, Male
Sex: Female, Male(Participants)Gral First, Then Neur, Lyr, and PlboNeur First, Then Plbo, Gral, and LyrLyr First, Then Gral, Plbo, and NeurPlbo First, Then Lyr, Neur, and GralTotal
Female13318
Male755724
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Schmidt P, Rao S. Effects of gabapentin, pregabalin and gastroretentive gabapentin on simulated driving, daytime sedation and cognition. Pain Manag. 2018 Jul 1;8(4):297-306. doi: 10.2217/pmt-2018-0005. Epub 2018 Apr 19. PubMed 29671676 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Nov 2015, 1 month.

Results were first posted in May 2020, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2017
First posted
Jun 7, 2017
StartActual
Sep 24, 2015
Primary completionActual
Nov 20, 2015
CompletionActual
Nov 20, 2015
Results first posted
May 13, 2020
Last update
Jun 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03179345
Lead sponsor
Depomed
Responsible party
Sponsor
First posted
Jun 7, 2017
Start date
Sep 24, 2015
Primary completion
Nov 20, 2015
Completion
Nov 20, 2015
Results posted
May 13, 2020
Last update
Jun 1, 2020

Study contacts

Head of R&D
study director · Depomed
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gabapentin · Pregabalin

Start the discussion